Le Lézard
Classified in: Health
Subjects: PDT, FDA

Oobli Becomes First Company to Receive FDA "No Questions" Letter for a Novel Sweet Protein Produced via Precision Fermentation


"No questions" letter from US Food and Drug Administration signals support for the safety of the Oubli Fruit Sweet Protein for use in food and beverages

DAVIS, Calif., March 20, 2024 /PRNewswire/ -- Oobli, the leading global sweet protein platform known for its healthy sugar alternatives, today announced it has received the "No questions" letter from the US Food & Drug Administration (FDA), accepting the Company's conclusion that the Oubli Fruit Sweet Protein (known by its scientific name as "brazzein") is Generally Recognized as Safe (GRAS) for use as a sweetener in food and beverages. 

"Oobli is changing the future of sweetness through the use of sweet proteins as a replacement for traditional cane sugar and other alternative sweeteners like aspartame, sucralose, stevia and erythritol," said Jason Ryder, Oobli Founder & CTO, and Adjunct Professor of Chemical and Biomolecular Engineering at University of California Berkeley. "The Oubli Fruit Sweet Protein is one of several sweet proteins that is derived from fruits primarily found in West Africa and other equatorial environments. Sweet proteins are a class of proteins that deliver a sugar-like sweetness but don't affect blood sugar, insulin or the gut microbiome."

Oobli is the first company to receive the "No questions" letter from the FDA for use of the Oubli Fruit Sweet Protein as a food ingredient. In fact, the company's brand name and sweet protein platform "Oobli'' was inspired by West African villagers who originally described the Oubli Fruit as being, "So sweet it makes children forget their mother's milk."

"The "No questions" letter from the FDA is a further testament to the strong potential that sweet proteins have to disrupt our global dependence on sugar and alternative sweeteners," said Ali Wing, CEO, Oobli. "The Oubli Fruit Sweet Protein can be safely used in various foods with support from the general scientific community and the FDA. It can replace 70% or more of sugar in most food and beverages such as sodas, teas, baked goods and more, making the opportunities to reduce our sugar consumption endless."

Oobli will sample its line of craft-brewed, low-sugar Sweet Teas, as well as its Dark and Milk Chocolates featuring the Oubli Fruit Sweet Protein, at the Future Food-Tech Conference in San Francisco from March 21-22.

About Oobli
Oobli has reimagined sweetness by unlocking the power of sweet proteins. Leveraging its proprietary fermentation process, Oobli uses tiny plant-based sweet proteins that keep blood sugar at bay and add healthy, gut-friendly sweetness to food and beverages. Oobli Sweet Tea and Oobli Chocolates deliver the same flavor and deliciousness of traditional sugar-sweetened treats but without any compromises on health or the planet. To learn more, visit oobli.com.

Media Contact
[email protected]

SOURCE Oobli


These press releases may also interest you

at 20:26
In the news release, Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Real-World Data at the Professional Society for Health Economics and Outcomes Research 2024 Annual Meeting, issued 03-May-2024 by Mitsubishi Tanabe Pharma...

at 20:00
Affiliated Dermatologists (AD) is providing notice of a recent data security incident. At this time, AD is not aware of any misuse of any personal information in connection with this incident. What Happened? On March 5, 2024, AD detected it was the...

at 19:19
With recent news of dairy cattle in the United States testing positive for the Highly Pathogenic Avian Influenza (HPAI) and reports of fragments of HPAI detected in pasteurized milk sold in the U.S., we understand that Canadians may be concerned...

at 19:01
Butterfly Medical Ltd, an early-stage medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), is excited to announce the hiring of Patrick MacCarthy as CEO. ...

at 18:33
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 18:29
Filament Health Corp. (Cboe CA: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors...



News published on and distributed by: